# Pizarra — PT-pseudo_2e0346bce3b3 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2e0346bce3b3
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 3.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.01 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.1 ng/mL
  - Prostate volume: 99.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7092595 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.5 ng/mL. PI-RADS 4. PSAD 0.01. Prostate volume 99 mL. csPCa 0.71.

Vitals: weight 68 kg, height 183 cm, BMI 20.3, BP 137/71 mmHg, HR 70 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2021).

Chief complaint: Assessment driven by a previously positive prostate biopsy and a steady upward trajectory in PSA measurements.

History: A 64-year-old delivery driver initially sought evaluation for elevated PSA levels in mid-2022, leading to a biopsy that confirmed low-grade disease. Following a divorce, he resides independently, with his adult daughter serving as his main point of contact. He experiences mild lower urinary tract symptoms, scoring a 6 on the IPSS scale, and manages these without alpha-blocker therapy. A smoking history of 31 pack-years was recorded before he ceased tobacco use in 2021; COPD remains stable, requiring only PRN salbutamol. He engages in light weight-training twice weekly at home and abstains from alcohol. Recent endocrinology consultations centered on routine thyroid screening, and he reports a right knee meniscectomy performed in his early twenties that remains stable without current functional limitations. There is no report of bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: The prostate presents as symmetrically enlarged yet smooth, lacking any palpable nodules or asymmetry. General assessment shows no abnormalities; height measures 183 cm, weight 68 kg, yielding a BMI of 20.3. Vital signs record a blood pressure of 137/71 mmHg and a heart rate of 70 bpm. Bilateral lung fields are clear, and the cardiovascular examination falls within normal limits.

Patient info: delivery driver; Divorced; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Light weight-training at home, 2x/week; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.30 +/- 0.28   (95% CI 0.00-0.84)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.28  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.88 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "is there cancer?" to "is the disease progressing or is the prior diagnosis confirmed/reclassified?". Specifically, it did not weigh the specific PI-RADS 4 score against the rising PSA velocity (0.63 ng/mL/yr) or the prior positive biopsy status. It also failed to incorporate the clinical significance of the csPCa probability of 0.7092595.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a $p=0.30 \pm 0.28$, placing it in the 'discuss' tier where the model cannot distinguish between biopsy and no biopsy. This is likely wrong because the guideline criterion explicitly states the decision *must* come from retrieved documents, and the prior failed to recognize that the prior positive biopsy status, combined with the current PI-RADS 4, necessitates a specific review pathway that the model missed. The high aleatoric uncertainty ($H=0.88$) suggests the model is highly uncertain because the data itself is ambiguous regarding the next step.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm. No comparison with a previous MRI was explicitly detailed in the report, but it is a new finding in the context of the re-evaluation.

get_psa_trend
PSA trend: [{"date": "Jun 2022", "val": 1.9}, {"date": "Apr 2023", "val": 2.3}, {"date": "Mar 2024", "val": 2.9}, {"date": "Jan 2025", "val": 3.5}]
The serial PSA trend shows a rising trajectory, increasing from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025.

get_previous_notes
Previous notes: {"date": "24 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "During a clinical review on 24 September 2024, a PSA increase to 3.1 ng/mL recorded in March was noted alongside a history of a previously positive biopsy. Routine laboratory panels returned within normal limits, and the patient continues to utilize salbutamol on an as-needed basis for COPD management."}
The prior biopsy was positive, and the patient was under a clinical review on 24 Sep 2024 noting a PSA increase to 3.1 ng/mL.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm.
- PSA trend: Serial PSA trend shows a rising trajectory, increasing from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025.

AGAINST Sampling this patient now:
- Previous notes: The prior biopsy was positive, and the patient was under a clinical review on 24 Sep 2024.

WHERE THIS LEANS
The evidence suggests progression given the rising PSA trend and the presence of a PI-RADS 4 lesion, which aligns with the guideline criterion requiring review of lesion change and PSA trajectory.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a rising PSA trend and a PI-RADS 4 lesion, aligns with the guideline criterion requiring review, leading to a lean towards biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "is there cancer?" to "is the disease progressing or is the prior diagnosis confirmed/reclassified?". Specifically, it did not weigh the specific PI-RADS 4 score against the rising PSA velocity (0.63 ng/mL/yr) or the prior positive biopsy status. It also failed to incorporate the clinical significance of the csPCa probability of 0.7092595.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a $p=0.30 \pm 0.28$, placing it in the 'discuss' tier where the model cannot distinguish between biopsy and no biopsy. This is likely wrong because the guideline criterion explicitly states the decision *must* come from retrieved documents, and the prior failed to recognize that the prior positive biopsy status, combined with the current PI-RADS 4, necessitates a specific review pathway that the model missed. The high aleatoric uncertainty ($H=0.88$) suggests the model is highly uncertain because the data itself is ambiguous regarding the next step.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm. No comparison with a previous MRI was explicitly detailed in the report, but it is a new finding in the context of the re-evaluation.

get_psa_trend
PSA trend: [{"date": "Jun 2022", "val": 1.9}, {"date": "Apr 2023", "val": 2.3}, {"date": "Mar 2024", "val": 2.9}, {"date": "Jan 2025", "val": 3.5}]
The serial PSA trend shows a rising trajectory, increasing from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025.

get_previous_notes
Previous notes: {"date": "24 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "During a clinical review on 24 September 2024, a PSA increase to 3.1 ng/mL recorded in March was noted alongside a history of a previously positive biopsy. Routine laboratory panels returned within normal limits, and the patient continues to utilize salbutamol on an as-needed basis for COPD management."}
The prior biopsy was positive, and the patient was under a clinical review on 24 Sep 2024 noting a PSA increase to 3.1 ng/mL.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 lesion located in the left posterior peripheral zone, measuring approximately 18 mm.
- PSA trend: Serial PSA trend shows a rising trajectory, increasing from 1.9 ng/mL in Jun 2022 to 3.5 ng/mL in Jan 2025.

AGAINST Sampling this patient now:
- Previous notes: The prior biopsy was positive, and the patient was under a clinical review on 24 Sep 2024.

WHERE THIS LEANS
The evidence suggests progression given the rising PSA trend and the presence of a PI-RADS 4 lesion, which aligns with the guideline criterion requiring review of lesion change and PSA trajectory.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the required documents. The evidence strongly leans towards biopsy based on the rising PSA trend and the PI-RADS 4 finding, despite the protocol criterion being inconclusive. The final decision rests with LLM-3-CHAIR.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The evidence leaned towards biopsy due to the rising PSA trend and the PI-RADS 4 finding, which supported the 'yes' position. However, the guideline criterion abstained because the retrieved documents did not provide a documented reason to proceed, such as a prior grade or lesion change against a named prior MRI. The statistical prior suggested no biopsy, and the retrieved evidence was insufficient to overturn this, resulting in a split decision. Therefore, deferral is chosen as no documented reason exists to change the management pathway.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
